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Following from the successful “RCEM weekly top five” series starting in April 2020, this is 
the first of a monthly format for EMJ readers.  We have undertaken a focussed search of 
the PubMed literature using a standardised COVID-19 search string. Our search between 
17th September and 31st October 2020 came up with 3,841 papers limited to human 
subjects and English language. 
 
Our team have narrowed down the most interesting, relevant and important of the papers 
and provided a critical snapshot of 5 of those we felt most deserved EMJ reader attention.  
Importantly we have highlighted not only the main findings from the papers but key 
limitations and considerations for EM clinicians when interpreting the work.  In doing so, 
have created a  accessible window into pertinent research findings for our busy 
colleagues during this fast-paced and ever-changing COVID-19 landscape. 
 
The papers are ranked in one of 3 categories, allowing you to focus on the papers that 
are most vital to your practice:
● Worth a pe k - interesting, but not yet ready for prime time 
● Head turner - new concepts
● Game changer - this paper could/should change practice
This month’s searches were undertaken by the “RCEM weekly top five” founders in 
Manchester and we look forward to next month’s instalment by our colleagues and 
neighbours in Salford.
Outcomes from intensive care in patients with COVID‐19: a systematic review and 
meta‐analysis of observational studies[1]
Topic: Outcome
Rating: Worth a peek
Arguably the greatest anxiety around the COVID-19 pandemic was ICU capacity for the sickest 
patients. This welcome meta-analysis including 24 observational cohort studies across Asia 
(mostly China), 6 countries from Europe and North America looked at outcomes for 10,150 
patients.
 
Overall ICU mortality was 41.6% (95% CI, 34.0-49.7) with the largest dataset (8826) coming from 
the UK’s Intensive Care National Audit & Research Centre. There was a progressive reduction in 
mortality over time, possibly reflecting the development of nascent expertise, new therapies, and 
expansion of capacity. Outcomes remained consistent after a sensitivity analyses, even after 
removing the UK data, a reassuring fact for the international medical community.  
 
There are inevitably shortcomings; uncompleted episodes for a condition with long lengths of stay 
means incomplete data. Morbidity data is also lacking for survival beyond ICU. Heterogeneity is 
significant; included papers vary  from single centre to national registry data. Most conspicuously 
absent are references to the antipodean data where an ICU mortality of 22.2% was reported this 
likely pertains to systems stress but warrants exploration.[2] 
We must remember that a summary statistic on overall ICU mortality is highly dependent on what 
defines ICU care combined with whatever real or perceived barriers to entering higher level care 
exist in different health economies. Despite this limitation the finding that ICU outcomes improved 
over time is reassuring.
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Bottom line: ICU mortality rate appears consistent worldwide and as the pandemic progresses, 
this meta-analysis suggests that it could also be reducing.




This paper from Emanuele et al. offers evidence for using lung ultrasound in the context of 
COVID-19. The authors conducted a prospective cohort study of patients presenting to the 
emergency department of an Italian academic hospital. Taking the premise that initial tests for 
COVID-19 (SARS–CoV-2 reverse transcription polymerase chain reaction, RT-PCR) have an 
important proportion of false-negative results, the authors sought to assess if combining lung 
ultrasound with clinical evaluation could facilitate the identification of false-negative RT-PCR 
results. In the absence of a true gold-standard test initial false negatives were determined by a 
positive result from a second RT-PCR performed within 72-hours of initial assessment. 
They enrolled 228 patients and found that clinical assessment with lung ultrasound had better 
sensitivity (94.4% vs. 80.4%) and negative predictive values (95% vs 85.2%) than first RT-PCR. 
They considered positive findings to include: presence of focal/diffuse interstitial syndrome 
associated with spared areas, subpleural consolidations and irregular/thickened pleural line
The authors argue that the presence or absence of changes consistent with COVID-19 (showing 
here a higher sensitivity than first  RT-PCR) not only influences the care of the patient themselves, 
but also impact healthcare systems by influencing treatment, infection control measures and 
quarantine of close contacts. 
However, in addition to the lack of a true gold standard test,  this study may have overestimated 
diagnostic accuracy as patients were assessed in an area where those with possible COVID-19 
symptoms were cohorted; operators were experienced at lung ultrasound; and non-pre-specified 
diagnostic criteria were used. 
Bottom Line – A patient with an initial negative RT-PCR for COVID-19 with clinical and ultrasound 
features suggestive of the disease should be considered positive and managed as such.
Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO 




Knight et al seek to answer the question of what might predict death from COVID-19. The 
authors derived and internally validated a model to predict mortality in COVID-19 patients 
admitted to hospital. They used the UK’s ISARIC dataset, using data from 57,824 patients 
admitted to hospitals with COVID-19.[5] The authors utilised logistic regression and machine 
learning (ML) techniques to derive an algorithm. The logistic regression model was converted 
into a simplified integer 4C score that can be easily calculated (available at 
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https://isaric4c.net/risk/), and the ML model was used as a comparator. Both models deliver a 
predicted mortality (expressed as a percentage) for an individual patient.
The 4C score performs almost as well as a discriminator as compared to the ML model with an 
area under the curve of 0.767 (0.760 to 0.773) vs 0.779 (0.772 to 0.785). Whilst the ML model 
was marginally better, the more usable, simpler 4C score is almost as good as the complicated, 
difficult-to-deploy ML version. 
The authors suggest that the model could be used when making the decision to admit patients. 
However as it was not derived in a group where patients were considered for admission but 
rather were already admitted, this means that it may not perform as well in a mixed in/out 
patient cohort. 
Clinical algorithms are typically finally evaluated through external validation studies, which 
would be good to see, although the pace and scale of the pandemic means that we may see 
this score entering practice before this final stage. 
 
Bottom line: The 4C score is derived from one of the largest COVID-19 datasets and given the 
unknown accuracy of clinician gestalt it may be the best predictive algorithm at this stage.
Measuring geographical disparities in England at the time of COVID-19: results using a 
composite indicator of population vulnerability[6]
Topic: Epidemiology
Rating: Worth a peek
 
Nicodemo et al created an index to highlight communities in England likely to be more exposed 
and vulnerable in a pandemic. They used clinical commissioning groups (CCGs) as their 
geographical level. To build their index of vulnerability, they applied  evidence from previous 
approaches in the literature to identify 15 variables that look at demand and supply-side factors 
influencing healthcare in a pandemic. They found that 80% of the most vulnerable CCGs are 
located in the North of England and that there was positive spatial correlation (Moran’s I, 
I=0.155, p=0.00) i.e. bordering CCGs have similar vulnerability scores. There was a positive 
correlation between their vulnerability index and COVID-19 deaths. Notably however there is no 
mention of the COVID-19 incidence and thus we cannot comment on whether these death rates 
are disproportionate to case load. 
A limitation of this index is that variables were equally weighted and dichotomised at the mean 
to create the score. As such, much of the information from the continuous data is lost, although 
the investigators found similar results when dividing the variables into quartiles. COVID-19 test 
data was available by hospital and therefore might not always represent the patient’s CCG of 
residence, introducing some inaccuracy. 
Nonetheless this paper presents a relevant scoring system which identifies areas at particular 
risk.  Alongside other indicators such a score may guide pandemic preparedness and response 
and healthcare system strengthening.
Bottom line: This index of vulnerability highlights areas at risk of the effects of the COVID-19 
pandemic, helping policymakers identify and target their support during further pandemic waves
Remdesivir for the Treatment of Covid-19 — Final Report[7]
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Topic: Treatment
Rating: Game Changer
The preliminary report on Remdesivir was published in May 2020, showing a reduced recovery 
time with its use, and resulted in an emergency use authorisation. Whilst never overwhelming, 
the evidence was deemed enough to add Remdesivir to the COVID-19 treatment box.
 
We now have the final report of this double-blind randomised placebo-controlled trial of 
hospitalised COVID-19 patients. 1062 patients were randomised to Remdesivir or placebo. 
Those receiving Remdesivir had a shorter median recovery time (10 versus 15 days) with a 
rate-ratio for recovery of 1.29 (95% CI, 1.12 to 1.49) i.e. those using Remdesivir had 1.29 times 
the rate of recovery as compared to placebo.  The authors highlighted a “trend” toward survival 
benefit with Remdesivir at 29 days however the study does not demonstrate statistical 
significance.
 
Controversial aspects to this study included: the repurposing of a phase two to a phase three 
trial; varying the placebo used across sites; potential crossover in the severity categorisation 
and a change in the trial’s primary outcome measure of mortality at 15 days to 29 days. Most 
criticism however points at the decision to stop the trial early, denying us more definitive 
evidence.
 
Of course, tides do turn, although perhaps never with such speed as we have seen in this 
pandemic.  The coming weeks may see the WHO SOLIDARITY trial halt Remdesivir in its tracks 
with its own emerging evidence suggesting no evidence of benefit in COVID-19.[8] Pending this 
full publication, at the time of this writing, WHO have just made a conditional  recommendation 
against the use of Remdesivir in COVID patients[9].
Bottom line: This trial demonstrated some evidence for Remdesivir utility in reducing time to 
recovery treating hospitalised COVID-19 patients but failed to significantly demonstrate survival 
benefit
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